Related Experiment Video
Updated: May 16, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Sustained disease control in transplant-ineligible patients: the role of continuous therapy
Antonio Palumbo1, Ruben Niesvizky
1Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria, San Giovanni Battista di Torino, Turin, Italy. appalumbo@yahoo.com
Abstract:
Many patients with multiple myeloma (MM) are elderly (aged >65 years) or unfit, and therefore ineligible for stem-cell transplantation. The novel agents thalidomide, bortezomib, and lenalidomide have shown improved outcomes in these patients. This article discusses the role of continuous therapy in improving patient outcomes and how novel agents with better tolerability profiles could lead to a change in the treatment paradigm. According to the proposed concept, treatment of transplant-ineligible patients with MM should include achievement of high-quality responses with effective induction combination regimens, as well as maintenance of the response with long-term therapy for optimal sustained efficacy.
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

